etoposide has been researched along with Plasmablastic Diffuse Large B-cell Lymphoma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castillo, JJ; Dittus, C; Miller, JA; Wehbie, R | 1 |
| Dhanushkodi, M; Jayachandran, PK; Karunakaran, P; Kesana, S; Mehra, N; Radhakrishnan, V; Rajan, AK; Sagar, TG; Selvarajan, G | 1 |
| Rais, H; Tazi, I; Tissir, R | 1 |
| Kobayashi, H; Miyagi, N | 1 |
| Arora, N; Gupta, A; Sadeghi, N | 1 |
| Ambinder, RF; Hunter, NB; Vogt, S | 1 |
| Dittus, C; Ellsworth, S; Grover, N; Park, SI; Tan, X | 1 |
| Baldini, F; Bibas, M; Cartron, G; Castillo, JJ; Cwynarski, K; Dierickx, D; Fedele, P; Gilbertson, M; Grigoriadis, G; Guerrero-Garcia, T; Lansigan, F; Linnik, Y; Mogollon, R; Navarro, JT; Ninkovic, S; Olszewski, AJ; Reagan, JL; Tchernonog, E; Tousseyn, T | 1 |
| Bai, QX; Chen, XQ; Dong, HJ; Feng, J; Gao, GX; Gu, HT; Liang, R; Shu, MM; Xu, L; Yang, L; Zhang, N | 1 |
| Fedele, PL; Gilbertson, M; Gregory, GP; Grigoriadis, G; Kumar, B; Opat, S; Shortt, J | 1 |
2 review(s) available for etoposide and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
[Isolated plasmablastic lymphoma of nasal mucosa in an immunocompetent patient achieving complete remission after multimodal treatment: about an African patient and literature review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Male; Middle Aged; Nasal Mucosa; Neoplasm Staging; Nose Neoplasms; Plasmablastic Lymphoma; Prednisolone; Remission Induction; Tomography, X-Ray Computed; Vincristine | 2020 |
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Plasmablastic Lymphoma; Prednisone; Rituximab; Vincristine | 2017 |
1 trial(s) available for etoposide and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Retrospective Studies; Survival Rate; Vincristine | 2019 |
7 other study(ies) available for etoposide and Plasmablastic Diffuse Large B-cell Lymphoma
| Article | Year |
|---|---|
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Neoplasm Recurrence, Local; Plasmablastic Lymphoma; Salvage Therapy | 2022 |
Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Vincristine; Young Adult | 2020 |
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Female; HIV Infections; Humans; Middle Aged; Plasmablastic Lymphoma; Prednisone; Remission Induction; Vincristine | 2017 |
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Retroviral Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Induction Chemotherapy; Male; Plasmablastic Lymphoma; Prednisone; Vincristine | 2017 |
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis.
Topics: Adult; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Retrospective Studies; Time Factors; Treatment Outcome; Vincristine | 2018 |
[Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; HIV Infections; Humans; Male; Middle Aged; Plasmablastic Lymphoma; Prednisone; Prognosis; Retrospective Studies; Vincristine | 2018 |
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Infusions, Subcutaneous; Male; Plasmablastic Lymphoma; Prednisone; Treatment Outcome; Vincristine | 2016 |